DK3191513T3 - Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma - Google Patents
Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma Download PDFInfo
- Publication number
- DK3191513T3 DK3191513T3 DK15760590.8T DK15760590T DK3191513T3 DK 3191513 T3 DK3191513 T3 DK 3191513T3 DK 15760590 T DK15760590 T DK 15760590T DK 3191513 T3 DK3191513 T3 DK 3191513T3
- Authority
- DK
- Denmark
- Prior art keywords
- eosinofile
- reslizumab
- asthma
- moderate
- severe
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title 1
- 229960003254 reslizumab Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047248P | 2014-09-08 | 2014-09-08 | |
| US201462091150P | 2014-12-12 | 2014-12-12 | |
| US201562168007P | 2015-05-29 | 2015-05-29 | |
| US201562191690P | 2015-07-13 | 2015-07-13 | |
| PCT/US2015/047357 WO2016040007A1 (en) | 2014-09-08 | 2015-08-28 | Use of reslizumab to treat moderate to severe eosinophilic asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3191513T3 true DK3191513T3 (da) | 2020-08-24 |
Family
ID=54066234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15760590.8T DK3191513T3 (da) | 2014-09-08 | 2015-08-28 | Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9815894B2 (da) |
| EP (1) | EP3191513B1 (da) |
| KR (1) | KR102495432B1 (da) |
| CN (1) | CN107073114B (da) |
| AU (1) | AU2015315628A1 (da) |
| CA (1) | CA2962944A1 (da) |
| CY (1) | CY1123501T1 (da) |
| DK (1) | DK3191513T3 (da) |
| EA (1) | EA034864B1 (da) |
| ES (1) | ES2811124T3 (da) |
| HR (1) | HRP20201307T1 (da) |
| HU (1) | HUE050202T2 (da) |
| PL (1) | PL3191513T3 (da) |
| PT (1) | PT3191513T (da) |
| RS (1) | RS60701B1 (da) |
| SI (1) | SI3191513T1 (da) |
| UA (1) | UA122670C2 (da) |
| WO (1) | WO2016040007A1 (da) |
| ZA (1) | ZA201702247B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| US20180056018A1 (en) * | 2016-08-31 | 2018-03-01 | Cephalon, Inc. | Inhalation Systems, Devices and Methods |
| US20200332344A1 (en) * | 2017-05-12 | 2020-10-22 | The Regents Of The University Of California | Treating and detecting dysbiosis |
| KR102709785B1 (ko) | 2017-09-29 | 2024-09-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용 |
| EP3836801A4 (en) | 2018-08-16 | 2022-05-18 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy with maintenance dose |
| CN113891722A (zh) | 2018-12-20 | 2022-01-04 | 爱沐疗法公司 | 用于漏服剂量的花生口服免疫疗法给药计划表 |
| CN113507938B (zh) | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| EP3965815A4 (en) | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR248044A1 (es) | 1992-02-06 | 1995-05-31 | Schering Corp | Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped. |
| USRE39548E1 (en) | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
| US6056957A (en) | 1994-08-04 | 2000-05-02 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-5 |
| AU2009228163B2 (en) | 2008-03-28 | 2012-08-30 | Glaxosmithkline Llc | Methods of treatment |
| WO2011156000A2 (en) | 2010-06-07 | 2011-12-15 | Aerovance, Inc. | Use of il-4/il-13 antagonists to treat eosinophilic disorders |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
-
2015
- 2015-08-28 WO PCT/US2015/047357 patent/WO2016040007A1/en not_active Ceased
- 2015-08-28 SI SI201531319T patent/SI3191513T1/sl unknown
- 2015-08-28 CN CN201580056209.2A patent/CN107073114B/zh active Active
- 2015-08-28 HR HRP20201307TT patent/HRP20201307T1/hr unknown
- 2015-08-28 UA UAA201703334A patent/UA122670C2/uk unknown
- 2015-08-28 EP EP15760590.8A patent/EP3191513B1/en active Active
- 2015-08-28 EA EA201790563A patent/EA034864B1/ru not_active IP Right Cessation
- 2015-08-28 PL PL15760590T patent/PL3191513T3/pl unknown
- 2015-08-28 RS RS20200977A patent/RS60701B1/sr unknown
- 2015-08-28 HU HUE15760590A patent/HUE050202T2/hu unknown
- 2015-08-28 DK DK15760590.8T patent/DK3191513T3/da active
- 2015-08-28 KR KR1020177009565A patent/KR102495432B1/ko active Active
- 2015-08-28 CA CA2962944A patent/CA2962944A1/en not_active Abandoned
- 2015-08-28 US US14/838,503 patent/US9815894B2/en active Active
- 2015-08-28 PT PT157605908T patent/PT3191513T/pt unknown
- 2015-08-28 ES ES15760590T patent/ES2811124T3/es active Active
- 2015-08-28 AU AU2015315628A patent/AU2015315628A1/en not_active Abandoned
-
2017
- 2017-03-30 ZA ZA2017/02247A patent/ZA201702247B/en unknown
- 2017-10-13 US US15/783,289 patent/US10577414B2/en active Active
-
2020
- 2020-08-17 CY CY20201100764T patent/CY1123501T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3191513B1 (en) | 2020-06-24 |
| US20160102144A1 (en) | 2016-04-14 |
| HRP20201307T1 (hr) | 2020-11-27 |
| CY1123501T1 (el) | 2022-03-24 |
| US10577414B2 (en) | 2020-03-03 |
| SI3191513T1 (sl) | 2020-12-31 |
| HUE050202T2 (hu) | 2020-11-30 |
| KR20170072197A (ko) | 2017-06-26 |
| CA2962944A1 (en) | 2016-03-17 |
| EA201790563A8 (ru) | 2017-11-30 |
| NZ730541A (en) | 2023-10-27 |
| US9815894B2 (en) | 2017-11-14 |
| EA201790563A1 (ru) | 2017-08-31 |
| AU2015315628A1 (en) | 2017-04-20 |
| KR102495432B1 (ko) | 2023-02-03 |
| EP3191513A1 (en) | 2017-07-19 |
| WO2016040007A1 (en) | 2016-03-17 |
| EA034864B1 (ru) | 2020-03-31 |
| ES2811124T3 (es) | 2021-03-10 |
| UA122670C2 (uk) | 2020-12-28 |
| RS60701B1 (sr) | 2020-09-30 |
| PL3191513T3 (pl) | 2021-02-08 |
| PT3191513T (pt) | 2020-07-31 |
| CN107073114A (zh) | 2017-08-18 |
| US20180030131A1 (en) | 2018-02-01 |
| CN107073114B (zh) | 2022-01-14 |
| ZA201702247B (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256209A (en) | Novel cannabinoid combination therapies for multiple myeloma (mm) | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3191513T3 (da) | Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma | |
| HUE066839T2 (hu) | Eljárások kardiovaszkuláris kockázat csökkentésére | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| LT3494962T (lt) | Skysta inhaliavimo kompozicija, apimanti rpl554 | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3215607T3 (da) | Phagterapi | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| DK3154543T3 (da) | PPAR-Forbindelser til anvendelse ved behandlingen af fibrotiske lidelser | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| HRP20181570T1 (hr) | Režim doziranja spoja fgf-18 | |
| DK3143123T3 (da) | Mikrorna-induktion af kardiologisk regenerering | |
| HUE049170T2 (hu) | Eljárás szubsztituált cikloszerinek elõállítására | |
| PL3226888T3 (pl) | Podawanie selektywnego transsygnałowego inhibitora IL-6 | |
| DK3169405T3 (da) | Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme | |
| DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |